Silvant Capital Management LLC Sells 34,028 Shares of Boston Scientific Corporation $BSX

Silvant Capital Management LLC cut its stake in Boston Scientific Corporation (NYSE:BSX) by 79.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,732 shares of the medical equipment provider’s stock after selling 34,028 shares during the quarter. Silvant Capital Management LLC’s holdings in Boston Scientific were worth $938,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Riverwater Partners LLC grew its holdings in Boston Scientific by 3.3% in the 2nd quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock valued at $333,000 after buying an additional 98 shares in the last quarter. IVC Wealth Advisors LLC boosted its position in shares of Boston Scientific by 4.9% in the second quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock valued at $236,000 after acquiring an additional 102 shares during the period. HHM Wealth Advisors LLC boosted its position in shares of Boston Scientific by 13.2% in the first quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider’s stock valued at $89,000 after acquiring an additional 103 shares during the period. Rise Advisors LLC grew its stake in shares of Boston Scientific by 13.9% in the first quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider’s stock valued at $85,000 after acquiring an additional 103 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC increased its position in Boston Scientific by 3.9% during the second quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock worth $294,000 after acquiring an additional 103 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,561,336.74. This represents a 21.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director directly owned 24,134 shares in the company, valued at approximately $2,371,889.52. The trade was a 34.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 175,782 shares of company stock valued at $17,742,314 in the last three months. Company insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

BSX has been the topic of a number of analyst reports. Evercore ISI restated an “outperform” rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 11th. BTIG Research reaffirmed a “buy” rating and issued a $132.00 price objective on shares of Boston Scientific in a report on Friday, November 21st. Needham & Company LLC reissued a “buy” rating and set a $121.00 target price on shares of Boston Scientific in a report on Friday, October 17th. Finally, Truist Financial raised their price target on Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $123.77.

Boston Scientific Trading Down 0.2%

Shares of BSX opened at $101.14 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a 52-week low of $85.98 and a 52-week high of $109.50. The firm has a market cap of $149.93 billion, a price-to-earnings ratio of 54.08, a PEG ratio of 2.02 and a beta of 0.58. The business’s fifty day moving average is $99.09 and its 200-day moving average is $102.28.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.04. The business had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.Boston Scientific’s revenue was up 20.3% compared to the same quarter last year. During the same period last year, the firm posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.